Burning Rock Biotech Limited, a Guangzhou, China–based developer of next-generation sequencing (NGS) diagnostics for precision oncology, is lightly covered on Wall Street. Jefferies upgraded the ADR to Hold in May 2026, but credible, dated price targets attributable to named analysts were not consistently available from reputable sources. One aggregator lists a single "Sell" rating with no published target, while others show a Hold with no target figure. Given this, the analyst-average method cannot be applied responsibly. Instead, the $15 objective reflects a technical recovery toward the shares' recent consolidation zone around the mid-$15s, where the stock traded as recently as early October 2026. It is a public-discussion and technical benchmark, not a consensus forecast.
As of the latest verified close, BNR traded at $12.39, near the lower portion of its 52-week range of $6.79 to $41.72. Reaching $15 implies a rise of about 21%, which is a substantial move for a company with a market capitalization near $130 million and average daily volume of only about 35,000 shares. The path would likely depend less on valuation rerating and more on fundamental proof: stabilizing revenue, a credible move toward breakeven, and evidence that its in-hospital and pharma research-and-development service lines can offset declines in legacy central-laboratory volumes.
Burning Rock's gross margin has remained strong near 75%, and recent commentary pointed to meaningful progress in narrowing losses and reducing cash burn. The company held roughly RMB 417 million in cash on its most recent balance sheet, providing a buffer while it transitions its revenue mix toward in-hospital testing and pharmaceutical research services. A constructive catalyst around its next earnings release, or an analyst upgrade accompanied by a first real price target, could reframe how the market values the stock and support a climb toward the $15 area.
The obstacles are material. Burning Rock remains unprofitable, with a trailing-twelve-month net loss of roughly RMB 68 million and negative earnings per share (EPS), so it has no meaningful price-to-earnings (P/E) multiple to anchor a valuation. Revenue has declined on an annual basis, and its pharmaceutical research-services revenue can be lumpy. China's healthcare environment—including pricing pressure on diagnostics and regulatory uncertainty—adds risk, while thin trading volume can amplify volatility in both directions and make a sustained recovery harder to hold.
The shares recently bounced from near $10 to a short-term high around $13.42, so that level acts as immediate resistance. Above it, the $15 zone—the fallback objective—represents the prior consolidation area. The far more distant 52-week high of $41.72 sits more than three times above the current price and reflects a period of much higher valuation; it should not be confused with a near-term target. On the downside, the 52-week low near $6.79 marks a longer-term support reference.
Because no named analyst has published a usable 12-month target, there is no consensus horizon to cite. Investors should treat any price objective for a stock this volatile as sensitive to near-term news. The most important upcoming items are the next earnings report and any guidance on revenue trajectory, cash burn, and the in-hospital and pharma-services mix, plus any new analyst initiations or rating changes. Macro factors such as interest-rate decisions and sentiment toward Chinese ADRs can also move the shares disproportionately given their low liquidity.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from evolving market conditions, technical behavior, and AI-driven analysis. For a low-liquidity name like BNR, these signals can help traders spot changes in trend and momentum more efficiently than manual chart review. Traders can use them to discover opportunities, track positions, and react to shifting conditions. Explore the signals to see how AI currently reads BNR's setup.
Can BNR reach $15? The question hinges on a roughly 21% advance from $12.39, a substantial move for a thinly traded, still-unprofitable diagnostics company. The case for the move rests on a high gross margin, a large cash cushion, and progress in narrowing losses; the case against it rests on declining revenue, negative earnings, and Chinese healthcare and regulatory risks. With effectively no usable analyst price targets, the $15 figure is a technical recovery benchmark rather than a consensus, and it should be read as a scenario to monitor—not a forecast. The next earnings release, revenue guidance, and any fresh analyst coverage will be the clearest signposts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that BNR and RVTY have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNR and RVTY's prices will move in lockstep.
| Ticker / NAME | Correlation To BNR | 1D Price Change % | ||
|---|---|---|---|---|
| BNR | 100% | +4.50% | ||
| RVTY - BNR | 25% Poorly correlated | -0.53% | ||
| ACRS - BNR | 24% Poorly correlated | +4.58% | ||
| STXS - BNR | 24% Poorly correlated | -12.62% | ||
| ANGO - BNR | 23% Poorly correlated | +2.90% | ||
| GKOS - BNR | 23% Poorly correlated | +4.64% | ||
More | ||||